ITM-91 by ITM Isotope Technologies Munich for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

New mRNA flu vaccine shows promise: Faster to produce, highly effective in mice

The study evaluates the efficacy of a new quadrivalent mRNA influenza vaccine, finding it to be highly immunogenic and protective in a mouse model. Compared

October 16, 2023

Complete Success Rate Not as High as Expected With Gel Stent Implant for Glaucoma

While the Xen 45 gel stent implant showed beneficial long-term outcomes for the treatment of open-angle glaucoma, a substantial proportion of patients needed follow-up operations

May 31, 2024

Kidney Cancer Highlights From ASCO 2023

In this exclusive MedPage Today video, Pavlos Msaouel, MD, PhD, of MD Anderson Cancer Center in Houston, highlights some of the important updates in advanced

June 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.